Advertisement

Introduction and History of Stereotactic Body Radiation Therapy (SBRT)

  • Yasushi Nagata

Abstract

Intracranial Stereotactic Radiosurgery (SRS) was a new treatment method for brain tumors introduced in the twentieth century to deliver tight spatial/temporal distribution using a high precision technique. The clinical experience from intracranial SRS, together with the technical developments in conventional RT, initiated the development of Stereotactic Body Radiation Therapy (SBRT) for extracranial tumors characterized by a very high dose per fraction, delivered in a short time. This was started at the Swedish Karolinska University hospital in 1991 with tumors in the liver and lungs by Bromgren and Lax [1–3]. In parallel this method was developed in Japan and clinically introduced in 1994 for lung tumors [4–6]. During the last 5 years of the nineties, SBRT was introduced in several centers in Europe, Japan and USA. Wulf and Herfarth in Germany reported theis clinical results on lung cancer in 2001, followed by Timmerman in USA in 2003. The early reports had already shown very promising results with regard to local control and toxicity for the hypofractionation schedules which were adopted with 10–15 Gy/fraction given in 3–5 fractions during a short time. However, due to the new aspects introduced in SBRT, clinical experience was initially accumulated at a very slow rate and it was only during the last decade that outcome data from several centers was available to confirm the initial promising results. In this session, the historical development of SBRT was reviewed.

Keywords

Stereotactic Body Radiation Therapy Gamma Knife Single High Dose Japan Clinical Oncology Group Initial Promising Result 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Lax I, Blomgren H, Näslund I, et al. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994;33:677–83.PubMedCrossRefGoogle Scholar
  2. 2.
    Lax I, Blomgren H, Larson D, et al. Extracranial stereotactic radiosurgery of localized targets. J Radiosurg. 1998;1:135–48.CrossRefGoogle Scholar
  3. 3.
    Blomgren H, Lax I, Näslund I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Acta Oncol. 1995;34:861–70.PubMedCrossRefGoogle Scholar
  4. 4.
    Uematsu M, Shioda A, Tahara K, et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients. Cancer. 1998;82:1062–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Uematsu M, Shioda M, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51:666–70.PubMedCrossRefGoogle Scholar
  6. 6.
    Arimoto T, Usubuchi H, Matsuzawa T, et al. Small volume multiple non-coplanar arc radiotherapy for tumors of the lung, head & neck and the abdominopelvic region. Tokyo: Elsevier; 1998.Google Scholar

Bibliography

  1. 3rd Acta Oncologica symposium on stereotactic body radiotherapy. Copenhagen: Acta Oncol. 2006;45:771–994.Google Scholar
  2. Bauman P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27:3290–6.CrossRefGoogle Scholar
  3. Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006;45:787–95.PubMedCrossRefGoogle Scholar
  4. Blomgren H, Lax I, Göranson H, et al. Radiosurgery for tumors in the body: clinical experience using a new method. J Radiosurg. 1998;1:63–74.CrossRefGoogle Scholar
  5. Blomgren H, Lax I, Näslund I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Acta Oncol. 1995;34:861–70.PubMedCrossRefGoogle Scholar
  6. Chang JY, Balter PA, Dong L, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;72:967–71.PubMedCrossRefGoogle Scholar
  7. Dawson L, Eccles C, Craig T. Individualized image guided iso-NTCP based liver cancer SBRT. Acta Oncol. 2006;45:856–64.PubMedCrossRefGoogle Scholar
  8. Fakiris A, McGarry RC, Yiannoustsons CT, et al. Stereotactic body radiation therapy for early-stage non-small cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75:677–82.PubMedCrossRefGoogle Scholar
  9. Guckenberger M, Meyer J, Wilbert J, et al. Intra-fractional uncertainties in cone-beam CT based image-guided radiotherapy of pulmonary tumors. Radiother Oncol. 2007;83:57–64.PubMedCrossRefGoogle Scholar
  10. Haedinger U, Wulf J. Quality assurance in stereotactic body radiation therapy. In: Kavanagh BD, Timmerman R, editors. Stereotactic body radiation therapy. Philadelphia: Lippincott, Williams & Wilkins; 2005.Google Scholar
  11. Hara R, Itami J, Kondo T, et al. Clinical outcomes of single-fraction radiation therapy for lung tumors. Cancer. 2006;1006:1347–52.CrossRefGoogle Scholar
  12. Herfarth KK, Debus J, Lohr F, et al. Stereotactic single dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001;19:164–70.PubMedGoogle Scholar
  13. Herfarth KK, Debus J. Stereotaktische Strahlentherapie von Lebermetastasen. Der Chirurg. 2005;76:564–9.CrossRefGoogle Scholar
  14. Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005;76:48–53.PubMedCrossRefGoogle Scholar
  15. Joyner M, Salter BJ, Papanikolaou N, et al. Stereotactic body radiation therapy for centrally located lung tumors. Acta Oncol. 2006;45:802–7.PubMedCrossRefGoogle Scholar
  16. Kavanagh B, Schefter T, Cardenes H, et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006;45:848–55.PubMedCrossRefGoogle Scholar
  17. Kavanagh BD, McGarry R, Timmerman RD. Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol. 2006;16:77–84.PubMedCrossRefGoogle Scholar
  18. Koong AC, Christofferson E, Le Q, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005;63.Google Scholar
  19. Koong AC, Le Q, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;58:1017–21.PubMedCrossRefGoogle Scholar
  20. Laagerward F, Van Sornsen de Koste J, Nijssen-Visser M, et al. Multiple “slow” CT scans for incorporating lung tumor mobility in radiotherapy planning. Int J Radiat Oncol Biol Phys. 2001;51:932–7.CrossRefGoogle Scholar
  21. Lee S, Choi E, Park H, et al. Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung. Lung Cancer. 2003;40:309–15.PubMedCrossRefGoogle Scholar
  22. Lehnert T, Golling M. Indikationen und Ergebnisse der Lebermetastasenresektion. Radiologe. 2001;41:40–8.PubMedCrossRefGoogle Scholar
  23. Leksell L. Stereotactic radiosurgery. J Neurol Neurosurg Psychiatry. 1983;46:797–803.PubMedCentralPubMedCrossRefGoogle Scholar
  24. Leksell L. The stereotactic method and radiosurgery of the brain. Acta Chir Scand. 1951;102:316–19.PubMedGoogle Scholar
  25. Loo BW, Chang JY, Dawson LA. Stereotactic ablative radiosurgery: what’s in a name. Pract Radiat Oncol. 2011;1:38–9.PubMedCrossRefGoogle Scholar
  26. McGarry R, Papiez L, Williams M, et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: phase I study. Int J Radiat Oncol Biol Phys. 2005;63:1010–15.PubMedCrossRefGoogle Scholar
  27. Mendez-Romero A, Wunderink W, Hussain S, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single-institution phase I–II study. Acta Oncol. 2006;45:831–7.PubMedCrossRefGoogle Scholar
  28. Nagata Y, Matsuo Y, Takayama K, et al. Survey of SBRT in Japan. Int J Radiat Oncol Biol Phys. 2009;75:343–7.PubMedCrossRefGoogle Scholar
  29. Nagata Y, Negoro Y, Aoki T, et al. Clinical outcomes of 3D conformal hypofractionated single high dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2002;52:1041–6.PubMedCrossRefGoogle Scholar
  30. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63:1427–31.PubMedCrossRefGoogle Scholar
  31. Norihisa Y, Nagata Y, Takayama K, et al. Stereotactic body radiation therapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008;72:398–403.PubMedCrossRefGoogle Scholar
  32. Onimaru R, Shirato H, Shimizu S, et al. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys. 2003;56:126–35.PubMedCrossRefGoogle Scholar
  33. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma. Cancer. 2004;101:1623–31.PubMedCrossRefGoogle Scholar
  34. Pannetieri V, Wennberg B, Gagliardi G, et al. SBRT of lung tumors: Monte Carlo simulation with PENELOPE of dose distributions including respiratory motion and comparison with different treatment planning systems. Phys Med Biol. 2007;52:4265–81.CrossRefGoogle Scholar
  35. Potter L, Steinberg M, Rose C, et al. American Society of Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2004;60:1026–32.CrossRefGoogle Scholar
  36. Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic radiation therapy for lung metastases. J Clin Oncol. 2009;27:1579–84.PubMedCrossRefGoogle Scholar
  37. Schefter T, Kavanagh B, Timmerman R, et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005;62:1371–8.PubMedCrossRefGoogle Scholar
  38. Shirato H, Shimizu S, Tadashi S, et al. Real time tumor tracking radiotherapy. Lancet. 1999;353:1331–2.PubMedCrossRefGoogle Scholar
  39. Takayama K, Nagata Y, Negoro Y, et al. Treatment planning of stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 2005;61:1565–71.PubMedCrossRefGoogle Scholar
  40. Timmerman R, Galvin J, Michalski J, et al. Accreditation and quality assurance for Radiation Oncology Group: multicenter clinical trials using stereotactic body radiation therapy in lung cancer. Acta Oncol. 2006;45:779–86.PubMedCrossRefGoogle Scholar
  41. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–9.PubMedCrossRefGoogle Scholar
  42. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;124:1946–55.PubMedCrossRefGoogle Scholar
  43. Timmerman RD, Park C, Kavanagh BD. The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol. 2007;27(Suppl.3):S101–12, Appendix.Google Scholar
  44. Timmermann R, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–6.CrossRefGoogle Scholar
  45. Wersaell P, Blomgren H, Lax I, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 2005;77:88–95.CrossRefGoogle Scholar
  46. Wulf J, Baier K, Mueller G, et al. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol. 2005;77:83–7.PubMedCrossRefGoogle Scholar
  47. Wulf J, Guckenberger M, Haedinger U, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006;45:838–47.PubMedCrossRefGoogle Scholar
  48. Wulf J, Haedinger U, Oppitz U, et al. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol. 2001;177:645–55.PubMedCrossRefGoogle Scholar
  49. Wulf J, Haedinger U, Oppitz U, et al. Stereotactic radiotherapy of primary lung cancer and pulmonary metastases: a non-invasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys. 2004;60:186–96.PubMedCrossRefGoogle Scholar
  50. Xia T, Li H, Sun Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66:117–25.PubMedCrossRefGoogle Scholar
  51. Yaes RJ, Patel P, Maruyama Y. On using the linear-quadratic model in daily clinical practice. Int J Radiat Oncol Biol Phys. 1991;20:1353–62.PubMedCrossRefGoogle Scholar
  52. Zimmermann F, Geinitz H, Schill S, et al. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer. 2005;48:107–14.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2015

Authors and Affiliations

  1. 1.Department of Radiation OncologyHiroshima University HospitalHiroshimaJapan

Personalised recommendations